相关实验视频

Updated: May 22, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

针对小细胞肺癌中的FOXP1相分离,化学疗法耐药性的机制

Yichun Tang¹, Yuchun Niu², Yi Chen¹

¹Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

Communications biology

|March 14, 2025

概括

通过调节SP8和HRR通路,FOXP1驱动小细胞肺癌中的化学抵抗. 用BRD4和PARP抑制剂准这个轴对新肺癌治疗有希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

小细胞肺癌 (SCLC) 仍然是一个重大挑战,因为获得的化学抵抗.
识别驱动化学抵抗的新型分子机制对于治疗进步至关重要.

研究的目的:

阐明FOXP1在SCLC中介化学抵抗中的作用.
为了研究由FOXP1调节的SCLC化学抵抗中的分子通路.
评估针对FOXP1通路的治疗策略.

主要方法:

在SCLC模型中分析FOXP1表达及其下游目标.
调查FOXP1在调节SP8表达和同源重组修复 (HRR) 途径中的作用.
评估FOXP1的核定位和液-液相分离.
结合BRD4和PARP抑制的体外和体内疗效研究.

主要成果:

通过其超级增强剂 (SP8-SE) 上调SP8表达,FOXP1显著增强SCLC中的化学抵抗.
SP8通过同类重组修复 (HRR) 途径调解化学阻力.
FOXP1形成点的核结构,表明其功能所必需的液态相隔离.
针对FOXP1-SP8-HR轴的BRD4和PARP的联合抑制显示出协同作用的瘤生长减少.

结论:

FOXP1是SCLC中化学抵抗的关键调解者和潜在生物标志物.
FOXP1-SP8-HR轴代表了克服SCLC化学抵抗的可行的治疗标.
针对FOXP1驱动的途径为新型SCLC治疗提供了一个有希望的策略.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...